前沿速览042期| CAR-T治B淋 前沿览新知
01
在既往接受CD19 CAR-T细胞治疗失败后的淋巴瘤患者中，增强型CAR-T细胞疗法的应用探索
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
第一作者：Svoboda J
N Engl J Med（IF=96.3）. 2025 May 8;392(18):1824-1835.
全文网址：https://www.nejm.org/doi/full/10.1056/NEJMoa2408771
02
大B细胞淋巴瘤患者中CD8(+) CAR-T细胞的两阶段分化
Two-stage CD8(+) CAR T-cell differentiation in patients with large B-cell lymphoma
第一作者：Cao G
Nat Commun（IF=14.7）. 2025 May 6;16(1):4205.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/pmid/40328775/
03
CAR-T细胞疗法耐药机制及增强策略
Mechanisms underlying resistance to CAR-T cell therapy and strategies for enhancement
第一作者：Wu A
Cytokine Growth Factor Rev（IF=9.3）. 2025 Apr 22:S1359-6101(25)00045-0.
全文网址：https://www.sciencedirect.com/science/article/abs/pii/S1359610125000450?via%3Dihub
04
回输前及回输后1个月的(18)F-FDG PET/CT用于预测接受CAR-T细胞治疗的B细胞非霍奇金淋巴瘤患者的预后
(18)F-FDG PET/CT for predicting prognosis of B-cell non-Hodgkin lymphoma patients treated with chimeric antigen receptor T cells: the value of pre-infusion and M1 image
第一作者：Yao X
Eur J Nucl Med Mol Imaging（IF=8.6）. 2025 May 13.
全文网址：https://link.springer.com/article/10.1007/s00259-025-07302-2
05
TRANSCAR：CD19 CAR-T细胞疗法在复发/难治性转化型惰性淋巴瘤中的真实世界结局
TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomas
第一作者：Stephan P
Blood Adv（IF=7.4）. 2025 May 1:bloodadvances.2025015834.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025015834/537083/TRANSCAR-Real-World-outcomes-of-CD19CAR-T-Cell
06
在CD5阳性的复发/难治性弥漫大B细胞淋巴瘤中，CAR-T细胞疗法较标准治疗具有更好的效果
CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy
第一作者：Luo H
Cancer Biol Med（IF=5.6）. 2025 May 6:j.issn.2095-3941.2024.0626.
全文网址：https://www.cancerbiomed.org/content/early/2025/05/06/j.issn.2095-3941.2024.0626
07
静脉注射免疫球蛋白（IVIG）治疗CAR-T细胞疗法相关严重神经毒性的患者
Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
第一作者：Mokhtari S
Int J Mol Sci（IF=4.9）. 2025 Apr 21;26(8):3904.
全文网址：https://www.mdpi.com/1422-0067/26/8/3904
08
CAR-T细胞治疗患者的的长期生活质量、认知功能、症状负担、细胞因子释放综合征和神经毒性
Long-Term Quality of Life, Cognitive Function, and Symptom Burden Among Chimeric Antigen Receptor T-Cell Recipients and Associated Cytokine Release Syndrome and Neurotoxicity
第一作者：Andersen L
JCO Oncol Pract（IF=4.7）. 2025 May 13:OP2400823.
全文网址：https://ascopubs.org/doi/10.1200/OP-24-00823?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
09
序贯CD19和CD20 CAR-T细胞治疗复发/难治性弥漫大B细胞淋巴瘤
Sequential CD19-20 CAR T-cell therapy for refractory/relapsed diffuse large B-cell lymphoma
第一作者：Xue F
Cytotherapy（IF=3.7）. 2025 Apr 17:S1465-3249(25)00686-3.
全文网址：https://celltherapyjournal.org/retrieve/pii/S1465324925006863
10
在亚裔复发/难治性弥漫大B细胞淋巴瘤患者中，Axicabtagene Ciloleucel 与既往疗法的疗效比较：ZUMA-1与REAL-TREND的匹配调整间接比较
Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND
第一作者：Locke FL
Hematol Oncol（IF=3.3）. 2025 May;43(3):e70100.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12065393/
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.5-15 valid until 2027.5
供稿与审核：临床开发与医学部